Aptevo Therapeutics Inc. (APVO): Price and Financial Metrics
GET POWR RATINGS... FREE!
APVO POWR Grades
- APVO scores best on the Value dimension, with a Value rank ahead of 84.28% of US stocks.
- The strongest trend for APVO is in Value, which has been heading up over the past 179 days.
- APVO's current lowest rank is in the Stability metric (where it is better than 1.82% of US stocks).
APVO Stock Summary
- APTEVO THERAPEUTICS INC's market capitalization of $11,711,043 is ahead of only 3.44% of US-listed equities.
- With a price/earnings ratio of 1.83, APTEVO THERAPEUTICS INC P/E ratio is greater than that of about just 1.79% of stocks in our set with positive earnings.
- APTEVO THERAPEUTICS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 123.02%, greater than the shareholder yield of 98.46% of stocks in our set.
- Stocks that are quantitatively similar to APVO, based on their financial statements, market capitalization, and price volatility, are AEIS, SLS, INM, FEMY, and GEOS.
- APVO's SEC filings can be seen here. And to visit APTEVO THERAPEUTICS INC's official web site, go to aptevotherapeutics.com.
APVO Valuation Summary
- APVO's price/sales ratio is 1.7; this is 19.05% lower than that of the median Healthcare stock.
- Over the past 80 months, APVO's price/sales ratio has gone down 3.1.
Below are key valuation metrics over time for APVO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| APVO | 2023-01-30 | 1.7 | 0.7 | 1.8 | -0.1 |
| APVO | 2023-01-27 | 1.8 | 0.8 | 1.9 | 0.0 |
| APVO | 2023-01-26 | 1.8 | 0.8 | 1.9 | 0.0 |
| APVO | 2023-01-25 | 1.8 | 0.8 | 1.9 | 0.0 |
| APVO | 2023-01-24 | 1.8 | 0.8 | 1.9 | 0.0 |
| APVO | 2023-01-23 | 1.8 | 0.8 | 1.9 | 0.0 |
APVO Growth Metrics
- Its 4 year net income to common stockholders growth rate is now at 77.29%.
- Its 5 year net income to common stockholders growth rate is now at 77.29%.
- Its 5 year revenue growth rate is now at -30.28%.
The table below shows APVO's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 6.779 | -18.963 | 6.397 |
| 2022-06-30 | 9.875 | -17.309 | 7.044 |
| 2022-03-31 | 12.985 | -19.292 | -28.898 |
| 2021-12-31 | 12.292 | -21.679 | -28.457 |
| 2021-09-30 | 11 | -23.922 | -29.238 |
| 2021-06-30 | 9.367 | -26.067 | -29.032 |
APVO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- APVO has a Quality Grade of C, ranking ahead of 39.4% of graded US stocks.
- APVO's asset turnover comes in at 0.162 -- ranking 213th of 682 Pharmaceutical Products stocks.
- BMRN, STAB, and OMER are the stocks whose asset turnover ratios are most correlated with APVO.
The table below shows APVO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.162 | 1.000 | -2.443 |
| 2021-03-31 | 0.151 | 1.000 | -1.971 |
| 2020-12-31 | 0.128 | 1.000 | -1.081 |
| 2020-09-30 | 0.326 | 0.441 | -1.130 |
| 2020-06-30 | 0.470 | 0.455 | -2.534 |
| 2020-03-31 | 0.495 | 0.367 | -1.580 |
APVO Price Target
For more insight on analysts targets of APVO, see our APVO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $65.67 | Average Broker Recommendation | 1.5 (Moderate Buy) |
APVO Stock Price Chart Interactive Chart >
APVO Price/Volume Stats
| Current price | $2.20 | 52-week high | $7.55 |
| Prev. close | $2.20 | 52-week low | $1.94 |
| Day low | $2.12 | Volume | 106,409 |
| Day high | $2.23 | Avg. volume | 109,441 |
| 50-day MA | $2.55 | Dividend yield | N/A |
| 200-day MA | $3.48 | Market Cap | 11.20M |
Aptevo Therapeutics Inc. (APVO) Company Bio
Aptevo Therapeutics, a biotechnology company, provides oncology and hematology therapeutics. Its marketed products include WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn; and HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B. The company was spun off from Emergent BioSolutions Inc. in 2016 and is based in Seattle, Washington.
Latest APVO News From Around the Web
Below are the latest news stories about APTEVO THERAPEUTICS INC that investors may wish to consider to help them evaluate APVO as an investment opportunity.
Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid TumorsNew PD-L1 x CD40 Candidate Built on Proprietary ADAPTIR™ Platform, Enters Pre-Clinical PipelineSEATTLE, WA / ACCESSWIRE / January 9, 2023 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company … |
Aptevo Therapeutics Inc. (NASDAQ: APVO) Has Been Trading Down. What Are The Prospects For The Future?Aptevo Therapeutics Inc. (NASDAQ:APVO) traded at $3.91 at close of the session on Monday, 12/12/22, made an upward move of 12.58% on its previous day’s price. Looking at the stock we see that its previous close was $3.47 and the beta (5Y monthly) reads 5.52 with the day’s price range being $3.81 – $7.20. The … Aptevo Therapeutics Inc. (NASDAQ: APVO) Has Been Trading Down. What Are The Prospects For The Future? Read More » |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on MondayWe're starting off the week with a look at the biggest pre-market stock movers traders need to know about for Monday morning! |
Why Harpoon Therapeutics Shares Are Trading Higher By 97%? Here Are 53 Stocks Moving In Monday''s Mid-Day SessionGainers HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM ) shares jumped 165.7% to $1.4350 after jumping around 118% on Friday. HTG Molecular Diagnostics, last month, posted a Q3 loss of $0.41 per share. Harpoon Therapeutics, Inc. (NASDAQ: HARP ) rose 97.3% to $2.27 after the company announced it presented updated interim results at ASH 2022 for novel T cell engager HPN217 in relapsed/refractory multiple myeloma. Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP ) gained 85% to $0.69 after the company announced the exclusive license of potential therapeutic or preventative humanized anti-SARS-CoV-2 monoclonal antibodies from Curia Global. Aptevo Therapeutics Inc. (NASDAQ: APVO ) shares climbed 65.6% to $5.68 after the company announced that APVO436, in combination with venetoclax and azaci... |
Crude Oil Rises Sharply; Adicet Bio Shares PlungeU.S. stocks traded higher midway through trading, with the Dow Jones gaining over 250 points on Monday The Dow traded up 0.84% to 33,757.34 while the NASDAQ rose 0.37% to 11,045.45. The S&P 500 also rose, gaining, 0.52% to 3,954.71. Also check this: Volatility In Markets Increases Ahead Of Fed''s Rate Decision Leading and Lagging Sectors Energy shares rose by 1.8% on Monday. Meanwhile, top gainers in the sector included Euronav NV (NASDAQ: EURN ), up 10%, and Frontline Ltd. (NYSE: FRO ), up 9%. In trading on Monday, consumer discretionary shares fell by 0.3%. Top Headline Coupa Software Inc (NASDAQ: COUP ) announced it will be acquired by Thoma Bravo for $8 billion. Coupa also reported its third-quarter financial results. Coupa entered into a definitive agreement to be acquired by Thoma... |
APVO Price Returns
| 1-mo | -3.93% |
| 3-mo | -23.34% |
| 6-mo | -48.72% |
| 1-year | -62.13% |
| 3-year | -69.72% |
| 5-year | -95.15% |
| YTD | -5.17% |
| 2022 | -70.52% |
| 2021 | -78.53% |
| 2020 | 299.98% |
| 2019 | -48.46% |
| 2018 | -70.05% |
Continue Researching APVO
Here are a few links from around the web to help you further your research on Aptevo Therapeutics Inc's stock as an investment opportunity:Aptevo Therapeutics Inc (APVO) Stock Price | Nasdaq
Aptevo Therapeutics Inc (APVO) Stock Quote, History and News - Yahoo Finance
Aptevo Therapeutics Inc (APVO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...